Part
1
Part
2
Part
3
参考文献
[1] PIC/S. Introduction of PIC/S[EB/OL].[2023⁃07⁃10]. https://picscheme.org/en/about.
[2] PIC/S. Bulgaria/BDA and Saudi Arabia/SFDA join PIC/S[EB/OL].(2023⁃06⁃12)[2023⁃07⁃10]. https://picscheme.org/en/news.
[3] PIC/S. Accession Procedure:Pre⁃accession[EB/OL].[2023⁃07⁃13]. https://picscheme.org/en/pre⁃accession.
[4] PIC/S. Accession Procedure:accession[EB/OL].[2023⁃07⁃13]https://picscheme.org/en/accession⁃procedure⁃accession⁃2.
[5] 新华网. 食药监总局加入国际人用药品注册技术协调会[EB/OL].(2017⁃06⁃19)[2023⁃07⁃13]. http://www.xinhuanet.com/politics/2017⁃06/19/c_1121172227.htm.
[6] 国家药品监督管理局. 国家药品监督管理局启动药品检查合作计划(PIC/S)预加入申请工作[EB/OL].(2021⁃09⁃29)[2023⁃07⁃13]. https://www.nmpa.gov.cn/yaowen/ypjgyw/202109⁃29162552105.html.
[7] PIC/S. Publication of revised Annex I ⁃ PIC/S GMP Guide(PE009⁃17)[EB/OL].(2023⁃08⁃25)[2023⁃08⁃27]. https://picscheme.org/docview/6607.
[8] 国家食品药品监督管理局. 药品生产质量管理规范无菌药品附录[S]. 2011⁃02⁃24.
[9] Pharmaceutical and Healthcare Sciences Society. Control strategy white paper⁃in manufacturing of sterile pharmaceutical/drug pro⁃ducts[EB/OL].(2014⁃10⁃28)[2023⁃02⁃01]. https://www.euro⁃peanpharmaceuticalreview.com/article/27741/control⁃strate⁃gies⁃sterile⁃pharmaceutical⁃product⁃manufacturing/.
[10] InternationalOrganizationforStandardization. ISO14644⁃1,Cleanrooms and associated controlled environments⁃Part 1:Classification of air cleanliness by particle concentration[S]. 2015⁃10.
[11] 国家药品监督管理局药品审评中心. 除菌过滤技术及应用指南[EB/OL].(2018⁃09⁃11)[2023⁃07⁃13]. https://www.cde.org.cn/zdyz/domesticinfopage?zdyzIdCODE=0af89737406527ed⁃4104d1b875a45f5e.
[12] ZHENG J W. Interpretation of the main changes in the draft of Annex 1 of EU GMP 2020 and analysis of the influence on the manufacture of sterile products in China[J]. Chem Pharm Eng,2020,41(2):65⁃69.(in Chinese)郑金旺. 2020版欧盟GMP附录1草案的主要变化解读及对国内无菌药品生产的影响分析[J]. 化工与医药工程,2020,41(2):65⁃69.
撰稿人 | 王丹、杨敬鹏
责任编辑 | 胡静
审核人 | 何发
2024-09-02
2024-09-04
2024-09-23
2024-08-28
2024-09-27
2024-08-27
2024-09-09
近年来,RNA疗法及其在疾病治疗中的潜力备受关注,今年诺贝尔生理学或医学奖授予微小RNA(microRNA)领域的研究更是将这一热度推向高峰。在新药研发蓬勃发展的今天,小核酸药物被视为继小分子药和抗体药之后的“第三次制药浪潮”的关键力量。
作者:崔芳菲
评论
加载更多